276 related articles for article (PubMed ID: 33662812)
1. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
5. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
6. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
8. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P; Klugman KP
BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
[TBL] [Abstract][Full Text] [Related]
9. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.
Pan-Ngum W; Kinyanjui T; Kiti M; Taylor S; Toussaint JF; Saralamba S; Van Effelterre T; Nokes DJ; White LJ
Vaccine; 2017 Jan; 35(2):403-409. PubMed ID: 27914740
[TBL] [Abstract][Full Text] [Related]
10. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
Baral R; Higgins D; Regan K; Pecenka C
BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
[TBL] [Abstract][Full Text] [Related]
11. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
Atwell JE; Lutz CS; Sparrow EG; Feikin DR
Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
Srikantiah P; Vora P; Klugman KP
Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
[TBL] [Abstract][Full Text] [Related]
13. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
Campbell PT; Geard N; Hogan AB
BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
[TBL] [Abstract][Full Text] [Related]
14. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
16. Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review.
Lang JC
J Math Biol; 2022 Feb; 84(4):26. PubMed ID: 35218424
[TBL] [Abstract][Full Text] [Related]
17. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
Wittenauer R; Pecenka C; Baral R
BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
[TBL] [Abstract][Full Text] [Related]
18. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
Fitzpatrick MC; Laufer RS; Baral R; Driscoll AJ; Feikin DR; Fleming JA; Jit M; Kim S; Koltai M; Li Y; Li X; Nair H; Neuzil KM; Pecenka C; Sparrow E; Srikantiah P; Ortiz JR
Vaccine; 2023 Nov; 41(48):7047-7059. PubMed ID: 37777450
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis.
Guo L; Deng S; Sun S; Wang X; Li Y
Lancet Glob Health; 2024 Jun; 12(6):e1005-e1016. PubMed ID: 38670132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
